Grifols to purchaseTalecris for $3 billion

Grifols SA of Spain plans to buy Talecris Biotherapeutics Holdings Corp., a U.S. maker of plasma medicines part-owned by Cerberus Capital Management LP, for more than $3 billion, according to people familiar with the matter.

The two sides plan to announce the deal—which Grifols will pay for using a mix of mainly cash and some stock—as early as Monday morning, the people said. The exact price couldn’t be learned.

[Wall Street Journal]